Two separate midstage programs reported activity in treatment-resistant mesothelioma. Researchers at MD Anderson disclosed early results for VT3989, a first-in-class YAP‑TEAD inhibitor that disrupts Hippo pathway signaling and showed tumor responses in heavily pretreated advanced solid‑tumor cohorts, including refractory mesothelioma. Independently, Vivace Therapeutics reported a 32% objective response rate in a midstage mesothelioma trial and is preparing a phase 3. Both reports add new therapeutic modalities to a disease with few effective options and will guide planning for randomized testing.